Hosted on MSN6d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with ...
WSAV Savannah on MSN2mon
Nose spray to treat depression? FDA approves first-of-its-kind medicine
NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to ...
pharmaphorum2y
FDA approves Janssen’s ketamine-based nasal antidepressant
The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...
Pharmabiz8d
US FDA grants Fast Track designation to Johnson & Johnson’s nipocalimab to treat adult patients with moderate-to-severe Sjögren’s disease
Johnson & Johnson announced that the US Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD) for the treatment of adult patients with ...
Investing10d
Johnson & Johnson’s nipocalimab gets FDA Fast Track for Sjögren’s disease
SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: JNJ) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for nipocalimab, intended for the treatment of adult patients ...
Yahoo Finance7d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab), to treat moderately to severely active Crohn's disease ...
Business Insider7d
FDA approves Johnson & Johnson’s TREMFYA in Crohn’s disease
The company states: “Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options ...
Yahoo Finance7d
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and ...
Pharm Exec7d
FDA Approves Johnson & Johnson’s Tremfya for Crohn Disease
Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States. The FDA has ...
Benzinga.com7d
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
FDA approved Johnson & Johnson’s Tremfya as the first IL-23 inhibitor with both SC and IV induction options for Crohn’s disease. Tremfya sales reached $3.67 billion in 2024, marking a 17% year ...
Yahoo Finance7d
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV ...